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Activation of CD40 on hepatocytes and cholangiocytes is critical for amplifying Fas-mediated apoptosis in the human liver.
C4b-Binding Protein (C4BP) has been reported to act as a potential surrogate ligand for CD40, suggesting that it could be
involved in modulating liver epithelial cell survival. Using surface plasmon resonance (BiaCore) analysis supported by gel
filtration we have shown that C4BP does not bind CD40, but it forms stable high molecular weight complexes with soluble
CD40 ligand (sCD154). These C4BP/sCD154 complexes bound efficiently to immobilised CD40, but when applied to
cholangiocytes they failed to induce apoptosis or proliferation or to activate NFkB, AP-1 or STAT 3, which are activated by
sCD154 alone. Thus C4BP can modulate CD40/sCD154 interactions by presenting a high molecular weight multimeric sCD154/
C4BP complex that suppresses critical intracellular signalling pathways, permitting cell survival without inducing proliferation.
Immunohistochemistry demonstrated co-localisation and enhanced expression of C4BP and CD40 in human liver cancers.
These findings suggest a novel pathway whereby components of the complement system and TNF ligands and receptors might
be involved in modulating epithelial cell survival in chronic inflammation and malignant disease.
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INTRODUCTION
Regulation of cholangiocyte survival is crucial for maintaining
epithelial cell integrity in the biliary tract. Immune-mediated
destruction of cholangiocytes in diseases including primary biliary
cirrhosis (PBC), allograft rejection and graft versus host disease
occurs as a result of increased apoptosis, mediated by activation of
tumour necrosis factor receptor family members (TNFr) [1]. We
have previously shown that apoptosis of human hepatocytes and
cholangiocytes is regulated by co-operative interactions involving
CD40 and CD95 (Fas) in which activation of cell surface CD40 by
its ligand CD154 results in the induction of Fas ligand (CD178)
and autocrine or paracrine activation of Fas [2,3]. CD40-activated
Fas-dependent apoptosis requires sustained activation of the
transcription factors cFos/cJun (AP-1) and STAT 3 to overcome
transient, short lived NFkB (RelA) activation and tip the balance
away from survival towards apoptosis [2,4]. In contrast CD40
activation of hepatic endothelial cells results in proliferation
associated with sustained upregulation of NFkB and an absence of
AP-1 activation [5].
The ability of CD40 to mediate epithelial cell apoptosis may
have evolved as a mechanism to clear infected cells. In support of
this, loss of functional CD154 in patients with X linked hyper IgM
syndrome or in mice with targeted deletions of CD154 results in
defective clearance of cryptosporidial infections of the biliary tract
associated with chronic inflammation, hyperplasia of the biliary
epithelium and tumours [6,7]. Thus CD40 may provide
a mechanism to limit cell proliferation and malignant trans-
formation following injury or infectio
Recent studies suggest that C4b binding protein (C4BP), an
inhibitor of C3 convertase of the classical and lectin pathways of
complement activation [8,9], can act as a surrogate ligand for
CD40 with the potential to activate B cells thereby linking the
innate immune system and complement activity [10]. The liver is
a major site of synthesis of both soluble and membrane associated
C4BP [11] prompting us to investigate whether C4BP could bind
CD40 on epithelial cells and thereby modulate cell survival.
Herein we report that C4BP can form stable high-molecular
weight complexes with soluble CD154 (sCD154), which despite
binding CD40, completely inhibit CD40-mediated apoptosis of
human cholangiocytes. Furthermore, we show using surface
plasmon resonance (Biacore), that C4BP does not bind directly
to CD40. Whereas activation of cholangiocyte CD40 by sCD154
produced transient upregulation of NFkB (Rel A), sustained
activation of AP-1 (cJun/cFos) and pSTAT 3 resulting in
cholangiocyte apoptosis [5], the sCD154/C4BP complex failed
to activate these pathways and resulted in inhibition of apoptosis
and enhanced cell survival. Thus C4BP can modulate CD40/
sCD154 interactions by presenting a high molecular weight
multimeric sCD154/C4BP complex that suppresses activation of
transcription factors that critically regulate cholangiocyte apoptosis
permitting survival without proliferation. These results demon-
strate a novel mechanism by which components of the innate
immune system can modulate the survival of epithelial cells
Academic Editor: Mark Cookson, Laboratory of Neurogenetics, National Institutes
of Health, United States of America
Received November 2, 2006; Accepted December 15, 2006; Published January
17, 2007
Copyright:  2007 Williams et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: Financial support was received in the form of a project grant (Ref 6/
C19953) from the Biotechnology and Biological Science Research Council. The
sponsor played no role in the design or conduct of the study and BBSRC approval
to submit the manuscript was a precondition of accepting the award.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: s.c.afford@bham.ac.uk
PLoS ONE | www.plosone.org 1 January 2007 | Issue 1 | e159during inflammation and infection. The results may also have
important implications for cellular transformation during epithelial
malignancy.
RESULTS
C4BP prevented CD40 mediated cholangiocyte
apoptosis but did not cause cell proliferation
On its own C4BP at concentrations of up to 50 ug/ml had no
effect on cholangiocyte apoptosis whereas treatment with 1 ug/ml
sCD154 increased apoptosis from 14.8+/23.8% ISEL positive
cells to 59.1+/27.5% (p,0.005) at 24 hours. When cells were
treated with a combination of sCD154 and C4BP the induction of
apoptosis observed with sCD154 alone was completely inhibited at
C4BP concentrations of 5 ug/ml or greater (18.2+/23.4% ISEL
positive cells). In contrast, addition of C4BP to the bile acid
Taurodeoxycholic acid (TDC) had no discernable effect (TDC
induced apoptosis 83.4+/27.63% cells; TDC and C4BP treated
cells 81.5+/26.7% ISEL positive cells) (figure 1a–c). The addition
of C4BP/sCD154 also had no effect on TDC mediated apoptosis
(data not shown).
Ki67 nuclear staining demonstrated that the sCD154/C4BP
complex did not effect cholangiocyte proliferation compared with
untreated control cells (figure 1d)
Analysis of C4BP/CD40/CD154 interactions with
surface plasmon resonance
Biacore analysis revealed the predicted binding between immobi-
lised CD40 and sCD154. However no binding was observed
between CD40 and C4BP under any conditions. The possibility
that sCD154 occupancy obscured potential C4BP-binding sites on
CD40 was excluded by challenging immobilised CD40 with C4BP
first, followed by sCD154. In this experiment binding and
dissociation of the ligand could be seen, whereas no interaction
between C4BP and CD40 was observed (figure 2).
To determine whether the lack of CD40/C4BP interaction was
due to the concentration of C4BP used in the system, a range of
C4BP concentrations were tested from 40 mg/ml up to 400 mg/ml
(figure 3a). No interaction was seen between CD40 and C4BP,
even at the highest achievable protein concentration. The
possibility that immobilisation of CD40 had altered the structural
conformation of the protein thereby preventing binding to C4BP
was eliminated by demonstrating that CD40 was able to bind
sCD154 before and after titration of C4BP (figure 3a). Subsequent
dissociation of the sCD154/C4BP complex was also clearly seen
over time.
To confirm the findings and to determine whether C4BP could
bind any component of the CD40/CD154 dyad, experiments
were carried out in which C4BP was immobilised on a CM5 chip
and soluble CD40 (sCD40) or sCD154 added. C4BP was again
unable to bind sCD40, confirming the findings with immobilised
CD40. However, C4BP did bind sCD154 in a dose-dependent
manner at concentrations of between 0.313 mg/ml to 10 mg/ml
(figure 3b). Under similar conditions, C4BP did not bind to either
immobilised CD95 (Fas) or CD178 (Fas Ligand) and did not affect
the ability of immobilised CD95 to bind soluble CD178 (Data not
shown).
Detection of high molecular mass C4BP/sCD154
complexes by gel filtration
Further confirmation of the binding interaction demonstrated by
Biacore was obtained by gel filtration chromatography using
Sephacryl - 300 where the presence of high molecular weight
C4BP/sCD154 complexes was detected. One hundred ul fractions
were collected from the column and assayed for the presence of
sCD154 using a commercially available ELISA kit. Column void
volume was determined using dextran blue exclusion. Cytochrome
C was used to identify the maximum elution volume for proteins in
Figure 1. Panel a) This histogram shows inhibition of sCD154 mediated
apoptosis by C4BP but not apoptosis induced by 0.2 mM TDC. * sCD154
or **TDC induced similar levels of cholangiocyte apoptosis when
experimental error was taken into account (59.7%+/27.5 and 83.4%+/
27.7 and respectively) relative to control (p,.005)***. C4BP + sCD154
reduced apoptosis to control levels (p,0.005) whereas C4BP had no
effect on TDC induced apoptosis (81.5%+/26.7). C4BP/sCD154 also had
no effect on TDC mediated apoptosis (data not shown) Panel b and c
show representative cytospins stained for fragmented DNA using ISEL.
Panel d) Histogram summary of the effects of sCD154 and C4BP on
Cholangiocyte proliferation. Primary human cholangiocytes were
cultured in 24-well culture plates and simulated with either sCD154,
C4BP or a mixture of both. Following incubation for 24 hours, the cells
were fixed and proliferation assessed by immunohistochemical staining
for Ki-67 antigen. No significant difference was seen between the un-
stimulated controls and treated samples, implying that sCD154, C4BP or
the mixture had any effect on cholangiocyte proliferation. These data
represent the mean of three different counted areas per well repeated
for three different liver preparations.
doi:10.1371/journal.pone.0000159.g001
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fractions that corresponded almost exactly to the elution volume
for Dextran blue, confirming the presence of C4BP/sCD154
complexes in excess of 1500kDa (figure 4). The small trailing edge
of the major pear (between 7–9 ml elution volume) suggests that
a small proportion of intermediate sized complexes of C4BP/
sCD154 may also be present but were not clearly separable using
this methodology. sCD154 was also detected in fractions
corresponding to cytochrome C, demonstrating that some un-
bound, sCD154 was also present, representing either an excess of
sCD154 or a small fraction that had dissociated from the C4BP/
sCD154 complex during the experiment.
NFkB (Rel A) cJun/cFos and STAT 3 activation in
cholangiocytes following co-incubation with CD154/
C4BP
We have previously shown [3,5] and confirmed here, that
activation of CD40 on cholangiocytes results in a transient rise
in NFkB activation and a sustained activation of ERK/JNK and
cFos/cJun (AP-1 subunits) and STAT 3 phosphorylation associ-
ated with death by apoptosis [5]. Activation of cholangiocyte
CD40 by sCD154 in the presence of C4BP resulted in no
statistically significant increase in transient nuclear NFkB levels
compared to control cells (media alone) when data from all four
separate experiments was analysed using laser densitometry.
However, in contrast to sCD154 alone, C4BP/sCD154 complexes
induced short-lived upregulation of the cFos subunit of the AP-1
heterodimer without an increase in cJun and pSTAT3 was
downregulated (figure 5 and 6).
Figure 2. Surface Plasmon Resonance (Biacore) analysis – This figure
shows the sensogram for interactions between immobilised CD40,
sCD154 (10 ug/ml) and C4BP (40 ug/ml). The human CD40 fusion
protein was immobilised onto an activated CM5 chip and sCD154, C4BP
or a mixture of both was flowed across the surface of the chip in various
combinations allowing adequate time for both association and
dissociation events. The chip was regenerated using between experi-
ments using 2 M glycine. Any change in surface plasmon resonance
due to binding of the soluble proteins to the immobilised CD40 was
seen as a change in response units on the sensogram.
doi:10.1371/journal.pone.0000159.g002
Figure 3. Biacore analysis – Panel a) This figure shows the sensogram
trace for the titration of C4BP binding across immobilised CD40. CD40
fusion protein was immobilised on an activated CM5 chip, to yield 2000,
500 and 100 response units on three separate channels. Soluble C4BP
was then flowed across the surface of the chip at increasing
concentrations. The chip was regenerated between the different
concentrations using 2M glycine. No binding or dose-response was
seen. The integrity of the CD40 was confirmed by the determining the
ability of the receptor to subsequently bind sCD154. Panel b) This figure
shows the sensogram for sCD154 binding to immobilised C4BP. C4BP
was immobilised on an activated CM5 research grade chip. sCD154 was
then flowed across the chip at increasing concentrations up to 10 ug/
ml. The chip was regenerated between concentrations using 2 M
glycine. Dose dependent binding of sCD154 was observed across the
concentration range. No binding was observed with an irrelevant fusion
protein (data not shown).
doi:10.1371/journal.pone.0000159.g003
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liver tissue
Little C4BP or CD40 expression was detected in normal liver
tissue; occasional portal vessels stained weakly for C4BP (figure 7
panel a) and weak CD40 staining was detected on perivenular
hepatocytes, sinusoidal endothelial cells and leukocytes infiltrating
portal tracts. Similar staining patterns were seen in liver biopsies
from patients with end-stage alcoholic liver disease. In PBC weak
staining for CD40 was detected within the inflammatory infiltrate,
sinusoidal endothelium and on proliferating ductules with C4BP
detected in occasional periportal hepatocytes and within the
inflammatory infiltrate. Stronger staining was seen in liver tissue
from patients with primary sclerosing cholangitis (PSC) where the
inflammatory infiltrate, sinusoidal endothelium and ductules
stained positively for CD40 and periportal hepatocytes and
inflammatory cells for C4BP (figure 7 panel b).
The staining pattern was different in liver tumours. Strong
staining for CD40 and C4BP was detected in tumour cells in
hepatocellular carcinoma and the tumour stroma, inflammatory
cell infiltrate and vessels were also positive. In cholangiocarcinoma
a similar pattern of expression was detected The strongest staining
for both C4BP (figure 7 panel c) and CD40 was observed in the
peri-tumour stroma at the margins of hepatic metastases from
colorectal carcinoma where tumour cells, stromal cells, the
surrounding inflammatory infiltrate and necrotic centres stained
strongly for C4BP. CD40 expression also showed a similar pattern
of staining but was absent from the necrotic centres. Hepatocytes
in the surrounding normal tissue were predominantly negative for
C4BP and CD40 (figure 7 panel c).
In selected samples of tumour tissue we carried out dual
immunofluorescence to look for cellular co-localisation of CD40
and C4BP. Figure 8 shows a representative section from a
cholangiocarcinoma specimen. C4BP and CD40 co-localised to
ductular structures within the tumour as well as surrounding
tumour cells. Cells within the surrounding stroma including the
mononuclear infiltrate also stained positively for both proteins.
DISCUSSION
Whilst constitutive expression of CD40 is low in the liver during
normal circumstances, it is widespread and increased during
inflammatory liver disease implying that it has a pivotal role in
regulation of host responses to injury [2,3,5,12]. Expression of
CD154, the natural ligand for CD40 is confined to a subset of
tissue-infiltrating T cells, macrophages and platelets and is tightly
regulated [3,13,14,15]. On T cells expression of CD154 is
transient requiring the constant presence of cytokines such as
IFNc and contact dependent mechanisms to permit mRNA
stabilisation and sustained expression of the protein [16]. These
observations suggest that CD40/CD154 interactions in vivo are
likely to be regulated by factors that influence expression and
function of the ligand, CD154 as well as the receptor CD40 [17].
The consequences of CD40 ligation vary depending on cell
type. In B cells CD40 ligation results in cell survival, immuno-
globulin isotype class switching and upregulation of ICAM-1 and
CD86, functions which are critical in determining B cell fate and
function [18]. On fibroblasts CD40 ligation results in upregulation
of ICAM 1, VCAM-1, IL-6, and proliferation [19]. On endothe-
lial cells, CD40 ligation results in NFkB-dependent cell prolifer-
ation [4] and upregulation of adhesion molecules and chemokines
[20], suggesting a role for CD40 in leukocyte recruitment during
inflammation. CD40/CD154 interactions can also regulate
epithelial cell fate [2,3,4,5,21,22]. The outcome of CD40 ligation
will depend on several factors including ligand concentration,
mode of presentation, receptor density, and the activation of
NFkB-dependent survival factors [23,24]. Such complex mechan-
isms possibly explain the diverse consequences of CD40 activation
on epithelial cells include activation, turnover and malignant
transformation [25,26].
Figure 4. Fractionation of C4BP/sCD154 complex by gel filtration. C4BP and sCD154 were incubated together at 37uC for 1 hour. After this time the
solution was eluted on a Sepacryl-300 with 100 ul fractions collected up to a final eluted volume of 20 ml, which encompassed void volume through
to the lower limit of the fractionation range ( Dextran blue to cytochrome C). Fractions were assayed for the presence of sCD154 using a commercially
available ELISA kit.
doi:10.1371/journal.pone.0000159.g004
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partner only, CD154. The report in 2003 by Brodeur and
colleagues suggested that the structurally unrelated complement
inhibitor C4BP could also bind CD40 and function as a surrogate
or competing ligand in place of CD154. These observations
suggested a novel interface between complement and B cell
activation. C4BP is synthesized by hepatocytes and activated
monocytes [27,28] and upregulated by inflammatory cytokines
including IFN-c, IL-6, and TNF-a [28,29] and by glucocorticoids
[30]. In addition to binding C4b, C4BP also has binding sites for
protein S [11], heparin [31], bacterial proteins [32] and serum
amyloid protein [33]. Because the liver is a major site of C4BP
synthesis, we investigated whether C4BP could modulate CD40-
mediated responses in cholangiocytes. We show that at concentra-
tions which are likely to be physiologically relevant [9,11], soluble
C4BP completely abrogates cholangiocyte apoptosis induced by
sCD154 confirming that C4BP can alter the outcome of CD40
signalling on epithelial cells. This effect was specific for CD40/
sCD154 because C4BP had no effect on apoptosis induced by the
cytotoxic bile acid TDC (figures 1a–1c). Assessment of Ki67
nuclear proliferation antigen showed that the presence of C4BP
maintained cell survival without causing proliferation, inferring
that cholangiocytes incubated with sCD154 together with C4BP
were held in G
0 since Ki67 detects all cells in cycle (figure 1d).
Given the report by Brodeur et al [10] we thought that the most
likely interpretation was that C4BP had bound cholangiocyte
CD40 directly and either inhibited or displaced CD154 binding
thereby modulating CD154-mediated signals. However, when we
investigated the nature of the C4BP/CD40/sCD154 binding
interaction using surface plasmon resonance (Biacore) analysis
with purified proteins, we found that CD40 was unable to bind
C4BP despite retaining the ability to bind sCD154 (figure 2). An
alternative explanation was that sCD154 obscured putative C4BP
binding sites or that C4BP could not bind CD40 under these
specific conditions. This explanation can be excluded because
when we repeated the experiments with C4BP followed by
sCD154 and found that binding of C4BP to CD40 was still
negligible although sCD154 subsequently bound as expected
(figure 2 middle panel). These data confirm that on its own C4BP
is unable to bind immobilised CD40. When a mixture of sCD154
and C4BP was flowed over the chip (figure 2 lower panel) binding
was achieved confirming in agreement with Brodeur and collegues,
that the presence of C4BP did not prevent sCD154 binding to
CD40 (see below). Altering the concentration of C4BP by 10 fold,
changing the coating concentration of immobilised CD40 or
flowing sCD40 over immobilised C4BP had no effect, confirming
that C4BP is incapable of binding CD40 under any of the
conditions described here.
In theory it remains possible that the recombinant CD40 used
in our experiments may differ in tertiary structure to its native
form making it incapable of binding C4BP. We feel this is unlikely
however because the recombinant protein retains full functional
ligand binding activity either when immobilised directly on the
BiaCore chip or coupled via immobilised monoclonal antibody
specific for CD40 (data not shown).
Thus we remain uncertain why some of our data differ from
those published by Broduer and collegues [10]. The presence of
CD154 either on a subset of B cells or in a non B cell
subpopulation of peripheral blood mononuclear cells could be
a factor in their studies. The absence of a C4BP effect in cells from
patients with CD40 mutations is more difficult to reconcile with
our data, although it is possible that the mutation caused a more
generalised defect rendering cells unresponsive to TNFr mediated
stimuli. Our data provide an explanation for some of the effects
they reported on restoration of class switching and proliferative
responses in cells with CD154 mutations. If C4BP binds the
mutant CD154 protein it could promote more effective cross-
linking of CD154 and CD40 and thereby restore binding and
functionality.
Our data confirm that C4BP does not prevent the binding of
sCD154, or in our hands, the C4BP/sCD154 complex to CD40.
Biacore analysis showed dose-dependent saturable binding of
C4BP to increasing concentrations of sCD154 (figure 3b).
Although the Biacore data are convincing in themselves, we
thought it important to confirm the formation of C4BP/sCD154
complexes using an alternative method, gel filtration, which
provided further evidence that CD154 forms stable high molecular
weight complexes with C4BP (figure 4). We then went on to
investigate the effect of C4BP/sCD154 complex on the major
signalling pathways involved in primary cholangiocyte survival,
NFkB (RelA), AP-1 (cJun/cFos) and STAT 3. We have previously
shown that activation of cholangiocyte CD40 leads to transient
RelA expression and sustained cJun/cFos and STAT 3 expression
[3,4] resulting in apoptosis. Surprisingly, despite the ability to bind
CD40 when the C4BP/sCD154 complex was used to activate
CD40 on cholangiocytes, we were unable to detect transient
activation of NFkB or sustained STAT3 phosphorylation and saw
only transient activation of the cFos subunit of the AP-1
Figure 5. Representative Western blots showing NFkB, c-Fos and c-Jun
and pSTAT 3 levels in response to CD154/C4BP stimulation. Aliquots of
nuclear or cytoplasmic extracts as appropriate (40 ug protein) from
cultured and stimulated primary human cholangiocytes were probed
for NFkB (panel I); c-Fos and c-Jun(panel II) or pSTAT3 content. Blots
were stripped and re-probed for beta-actin which allowed for normal-
isation of data for variations in protein loading.
doi:10.1371/journal.pone.0000159.g005
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the presence of C4BP can prevent sCD154 mediated cholangio-
cyte apoptosis and suggests further complexities to CD40 mediated
signalling in relation to cholangiocyte survival.
Our previous comparisons of CD40 mediated NFkB and AP-1
signalling in cholangiocytes and endothelial cells provide evidence
for cell-specific differences in transcription factor activation
following CD40 ligation [4,5]. In contrast to cholangiocytes,
activation of CD40 on endothelial cells resulted in sustained
activation of NFkB and no effect on the AP-1 pathway, the net
result being cell proliferation. In the present study, our initial
predictions were that the C4BP/sCD154 complex would function
to crosslink CD40 more efficiently than sCD154 alone leading to
more effective receptor crosslinking and as a consequence, an
increase in NFkB and AP-1 (cJun/cFos) activation in cholangio-
cytes. However, this was not the case and the C4BP/sCD154
complex suppressed the activation of these signalling pathways
resulting in cell survival in the absence of proliferation.
The ability of C4BP to modulate the outcome of sCD154
interactions with CD40 suggests the complement system may be
involved in regulate epithelial cell survival in the liver. Pro-
longation of epithelial cell survival is important to facilitate normal
protective immune responses, but if sustained could theoretically
facilitate malignant transformation. Furthermore, C4BP could
potentially modulate CD40 signalling in other cells including
endothelial cells, infiltrating leukocytes and stromal cells, which
could lead to perpetuation of inflammation. A link between
inflammation and malignancy is supported by our finding that
C4BP is expressed strongly in the reactive stroma at tumour
margins in association with CD40 expression on tumour cells
(figure 7 & 8). Interestingly, C4BP protein was also strongly
expressed in inflammatory cells and proliferating bile ductules in
PSC, a disease associated with a high risk of for malignant trans-
formation of biliary epithelium and the development of cholan-
giocarcinoma. Thus the presence of C4BP in close proximity to
tumor cells expressing the CD40 receptor could suppress the
induction of CD40-mediated apoptosis by CD154 effector cells
and favour tumour cell survival. The presence of C4BP in this
setting may also prevent complement mediated lysis of the tumour
cells.
MATERIALS AND METHODS
Isolation and culture of primary cholangiocytes
Cholangiocytes were isolated from a) liver tissue obtained from
fully informed consenting patients undergoing transplant surgery
for end-stage liver disease b) normal donor liver surplus to
transplant requirements. Ethical permission for the use of human
liver tissue for research was granted by the local research ethics
committee (ref 06/Q702/61)
The cells were isolated and cultured according to the protocol
previously described [3] with the minor modification of sub-
stitution of 10% v/v heat inactivated foetal calf serum for 10% v/v
heat inactivated human serum (HD Supplies UK) in the culture
medium. Primary isolated cells were expanded in 75 ml tissue
culture flasks for a maximum of 7 passages to ensure phenotypic
Figure 6. Densitometry Histograms showing changes in NFkB, c-Fos and c-Jun and pSTAT3 levels in response to sCD154 and C4BP stimulation
determined using Western blotting (see figure 5). Changes in levels were assessed by densitometric analysis. These data show that the CD154/C4BP
complex had no significant influence upon levels of NFkB or c-Jun, but did decrease levels of c-Fos at 24 hours compared with either unstimulated 24
hour control or the stimulated level observed at 4 hours. *p,0.05 a p,0.05These data show that stimulation of cells with CD154/C4BP complex
resulted in a lower level of pSTAT3 which was sustained at 24 hours. *p,0.05 c.f. time point matched untreated control a p,0.05 c.f. treatment
matched 4 hour time point.
doi:10.1371/journal.pone.0000159.g006
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recovered via gentle trypsinization and plated onto collagen
coated 4 well chamber slides (supplier) for 24–48 hours at an initial
density of 2610
5 cells per well in 0.5 ml of culture medium.
The effect of C4BP on CD154/CD40 mediated
cholangiocyte apoptosis and proliferation
The cholangiocyte cultures were incubated for up to 24 hours in
a) medium alone b) 1 ug/ml recombinant sCD154 (Alexis
Biochemicals product no. ALX-522-015), a concentration pre-
viously shown to provide optimal induction of apoptosis in these
cells [3] c) 1 ug/ml CD154+0.5–50 ug/ml purified native C4BP
[11]. In order to exclude a direct effect of C4BP were incubated
with d) 0.5–50 ug/ml C4BP alone e) C4BP in the presence of
0.2 mM of the proapoptotic bile acid TDC [12]. At the end of the
experiments, the cells were fixed in methanol and assessed for
apoptosis using DNA in situ end labelling [3,5,15]. Data from the
initial experiments informed us that 5 ug/ml C4BP was the
minimum concentration required to completely inhibit apoptosis
induced by 1 ug/ml sCD154. All subsequent experiments were
therefore carried out using these concentrations unless stated
otherwise. Cellular proliferation was assessed by measuring Ki-67
after epitope retrieval. Briefly, cells were fixed in situ with
methanol and treated with cells with W-CAP Tec buffer pH 8.0
(Bio-Optica, Milan, Italy) for 40 minutes at 96uC. Plates were
washed twice at room temperature with Tris-Buffered Saline
(TBS, pH 7.6) containing 0.1% Tween-20 (Sigma, Dorset, UK)
and cells stained with mouse monoclonal anti-human Ki-67 (Dako
Ltd, Cambridge, UK) at a 1/25 dilution at room temperature for
1 hour and washed twice as above. Bound Ki-67 monoclonal
antibody was then visualised using a ChemMate DAKO Envision
Detection Peroxidase/DAB Kit (Dako Ltd, Cambridge, UK;
according to the manufacturer’s instructions), followed by counter-
staining with Meyer’s Haematoxylin (VWR International Ltd,
Dorset, UK) for 20 seconds. Cells were scored for the presence of
Ki-67 positive nuclei using light microscopy, counting three
different random areas per well (min 200 cells/well).The experi-
ment was carried out using cells obtained from three different liver
preparations.
Analysis of C4BP/CD40/sCD154 binding interactions
by surface plasmon resonance (Biacore)
C4BP/CD40/sCD154 binding interactions were characterised
by Surface Plasmon Resonance(SPR) using the Biacore 3000
Figure 7. Immunolocalisation of C4BP in human liver tissue. This figure shows three representative sections of liver tissue stained for C4BP. Panel
a shows normal liver tissue which is predominantly negative. Panel b shows PSC liver tissue showing the presence of strongly staining inflammatory
cells surrounding the portal tract and within the sinusoids. Panel c shows hepatic tumour tissue taken from a hepatic resection for secondary liver
cancer (colorectal hepatic metastasis) where very strong staining was observed in the tumour tissue and the inflammatory infiltrate at the tumour
margin.
doi:10.1371/journal.pone.0000159.g007
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Experiments were carried out at 25uC using Biacore HBS-EP
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% surfac-
tant P20). CM5 chips were activated by a 7-minute injection
(5 ml/min) of a solution containing a 1:1 mixture of 0.2 M N-ethyl-
N9-(dimethylaminopropyl) carbodiimide (Sigma) and 0.05 M
N-hydroxy-succinimide (Sigma). One channel was blocked using
a 5-minute injection (10 ml/min) of 1 M ethanolamine (Sigma), in
order to serve as the control/reference channel.
In the initial experiments, a human CD40 murine-IgG fusion
protein (Ancell) was immobilised on channels 2–4 of the chip, at
a concentration of 10 mg/ml and a flow rate of 5 ml/min for
10 minutes. After immobilization, each surface was blocked by a
5-minute injection of 1 M ethanolamine at pH 8.5 at a rate of
10 ml/min. Following immobilization and blocking, sCD154 (the
analyte) was passed over the surfaces for 5 minutes at a concen-
tration of 10 mg/ml in HBS-EP buffer, followed by 5-minute
dissociation. After this time, purified C4BP [11] was passed over
the chip surfaces for 5 minutes at a concentration of 40 mg/ml,
followed by 5-minute dissociation. Chip surfaces were then
regenerated by two 1-min injections of 2 M glycine (pH 2.0,
Sigma).
Once regenerated, the experiment was repeated flowing C4BP
(40 ug/ml) across the chip first followed by sCD154 (10 ug/ml)
in HBS –EP buffer, for 5 minutes on each occasion, followed a
5-minute dissociation interval. After regeneration as described
above, a mixture of C4BP and sCD154 was flowed across the
channels on the chip for the same lengths of time and dissociation
as described. Any protein–protein interactions between sCD154
and/or C4BP and the immobilized CD40 were reported as
sensograms with data recorded as response units (ru) versus time
(seconds).
In subsequent experiments, recombinant CD40 (10 mg/ml) was
immobilised on an activated CM5 chip at 2000, 500 and 100 ru
on channels 2, 3 and 4 respectively. After immobilization, each
surface was blocked as described, and C4BP, sCD154 or a mixture
of both passed over the surfaces. Chip regeneration was achieved
by 261 min injections of 2 M glycine between each experiment. A
titration was then set up using increasing concentrations of C4BP
spanning a range from 40 mg/ml to 400 mg/ml. Each concentra-
tion was flowed across the surface of the chip (5 ml/min) for
5 minutes, followed by 5 minutes dissociation. Chip surfaces were
regenerated as described before and the subsequent concentration
was examined. Protein–protein interactions were recorded as
sensorgrams as described above.
In view of the failure to demonstrate interaction between CD40
and C4BP (see results), we carried out an additional experiment
where C4BP was immobilised on the chip surface. The chip was
activated and one channel blocked as described to serve as the
reference/control. C4BP (20 mg/ml) was immobilised onto
channels 2, 3 and 4 at pH values pf 4.2, 5.0 and 5.6 respectively
(to confirm optimal pH for immobilisation). An injection rate of
5 ul/min for 10 minutes was used. Each surface was subsequently
blocked with 165-minute injection of 1 M ethanolamine at
pH 8.5 at a rate of 10 ml/min. sCD154 was then passed over
the chip at concentrations from 0.31 mg/ml to 10 mg/ml. Each
concentration was flowed across the surface of the chip at
2 ml/min for 120 minutes, followed by 60 minutes dissociation.
Figure 8. Co-localisation of C4BP and CD40 in liver tumour tissue using dual immunofluorescence. Panels a–c shows a representative section of
tumour tissue from a patient with cholangiocarcinoma stained for C4BP (green - FITC) and CD40 (red - PE ). In panel a, the arrows identify an epithelial
ductular structure (DS) surrounded by tumour cells (TC) and stromal tissue. Positive C4BP staining is seen within the epithelia, tumour cells, and in
mononuclear infiltrate in the surrounding stromal tissue. Panel b shows the same tissue section stained for CD40 with the arrow identifying the
inflammatory cells within the surrounding stroma. Panels d and e shows a sequential section from the same specimen where the primary antibodies
have been substituted for non immune serum (control). Panel c shows the merged image for panels a and b. The bright yellow areas indicate regions
of C4BP and CD40 co-localisation within the epithelial cells of the ductular structure, many surrounding tumour cells, and the inflammatory cells
within the surrounding stromal tissue.
doi:10.1371/journal.pone.0000159.g008
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concentration was examined and protein–protein interactions
between C4BP and sCD154 were reported as sensorgrams. In
additional control experiments the ability of C4BP to bind
immobilised CD95 (Ancell, Bayport, USA, cat no. 506–020) or
CD178 (Alexis Biochemicals, UK, cat no. ALX-522-001) was
assessed under the same conditions.
Analysis of C4BP/sCD154 interaction by gel filtration
A mixture of C4BP and sCD154 (5 ug:1 ug) was incubated at
37uC for 1 hour with occasional agitation prior to gel filtration
chromatography on Sephacryl–300 (separation range (10kDa–
2500kDa) under the following conditions. Sephacryl-300
(Pharmacia) was poured into a 2061 cm glass gel filtration
column (BioRad) and packed using gel filtration buffer (0.1 M
NaPO4, pH 7.4, containing 0.15 M NaCl) at a flow rate of
1 ml/min. The column was then washed with the equivalent of
3 column volumes (20 ml) of buffer. The void volume was
determined using Blue Dextran (Sigma), while the retention of
.14kDa proteins was assessed using bovine heart cytochrome C
(Sigma). Fractions were collected (100 ml) up to the retention
volume for Cytochrome C and subsequently assayed for the
presence of CD154 using a commercially available ELISA kit
(Bender MedSystems, UK).
NFkB (Rel A), cFos/cJun and STAT 3 activation in
cholangiocytes following co incubation with
sCD154/C4BP
Our previously published studies have shown that cholangiocyte
stimulation via CD40 [3–5] results in transient NFkB (Rel A)
activation whereas AP-1 (cJun/cFos) and STAT 3 activation is
upregulated and sustained. In view of these findings, and the anti-
apoptotic effect of C4BP we investigated NFkB (Rel A) cFos/cJun
and STAT 3 activation following C4BP/sCD154 co-stimulation.
Western blotting with specific antibodies to the functional tran-
scription factors (see below) was carried out on cellular nuclear
protein extracts. This approach has been previously described and
shown to agree with results obtained by Electrophoretic Mobility
Gel Shift Assay [4,5]. Cholangiocyte monolayers were treated with
sCD154 (final concentration 1 mg/ml), C4BP (final concentration
5 mg/ml) or both for either 4 or 24 hours. After these times,
monolayers were harvested by scraping into cold PBS. Nuclear
protein extracts were prepared as previously described [5] and
protein content of each sample determined using the Micro Lowry
Total Protein Kit (Sigma, Dorset, UK; according to the manu-
facturer’s instructions). Samples (40 mg protein) were resolved on
a 10% Bis-Acrylamide gel by SDS-PAGE, followed by transfer to
nitrocellulose membrane (Amersham Pharmacia Biotech, Buck-
inghamshire, UK). Membranes were blocked overnight at 4uCi n
phosphate-buffered saline (PBS) containing 5% w/v non-fat dried
milk and then washed (3630 mins.) with 0.1%Tween-20/PBS,
before incubating with primary antibodies. All incubations were
for 1 hour at room temperature in Tween/PBS containing 5%
w/v non-fat dried milk. The following antibodies were used; a)
NFkB mouse monoclonal primary antibody (mAb) at 1/3000
dilution (Santa Cruz Biotechnology Inc. Cat. No. SC-8008). b)
c-Fos rabbit polyclonal primary antibody at 1/2000 dilution
(Santa Cruz Biotechnology Inc. Cat. No. SC-52). c) c-Jun rabbit
polyclonal primary antibody at 1/2000 dilution (Santa Cruz
Biotechnology Inc. Cat. No. SC-44). d) STAT3 mAb at 1/1000
dilution (Santa Cruz Biotechnology Inc. Cat. No. SC-8019). e)
phospho-STAT3 mAb at 1/1000 dilution (Santa Cruz Bio-
technology Inc. Cat. No. SC-8059). f) b-actin mAb at 1/2500
dilution (Sigma, Cat. No. A5441).
Following incubation with primary antibodies, the membranes
were washed as described above and mAb detected using horse
radish peroxidase (HRP) conjugated rabbit anti mouse IgG
(1/1000 for 1 hour at room temperature). Primary polyclonal
rabbit antibodies were detected using HRP conjugated goat anti
rabbit IgG (1/1000 dilution for 1 hour at room temperature; Dako
Ltd, Cambridge, UK). Membranes were then washed as before
and protein bands visualised using an enhanced chemilumines-
cence detection system (Pierce Perbio, UK) followed by exposure
to Hyperfilm-ECL (Amersham Pharmacia Biotech). Quantifica-
tion of the protein bands was determined using densitometry
scanning (BioRad 2000 Gel Doc system). Equality of protein
loading onto membranes and complete transfer was confirmed by
probing for b-actin and staining gels with Coomassie blue. All
Western immunoblots were performed using nuclear extracts
(NFkB, c-Fos and c-Jun) or cytoplasmic extracts (STAT3 and
phospho-STAT3) prepared from cholangiocytes isolated from
a minimum of three different human liver preparations.
Immunolocalisation of C4BP and CD40 in human
liver tissue
Immunohistochemistry was carried out according to a standard
protocol on serial 4 micron sections of snap frozen acetone fixed
liver tissue from normal (donor) liver or samples from patients with
cholangiocarcinoma, hepatic metastases, primary sclerosing cho-
langitis or end stage alcoholic cirrhosis (n=3–5 for each). Sections
were first blocked (20 mins room temp.) with 20% normal rabbit
serum (NRS) in Tris buffered saline pH 7.4 (TBS). Primary
antibodies used were either (monoclonal) mouse anti human
CD40 at 1:50 dilution (Alexis Corp.) or mouse anti human C4BP
at 1:25 dilution (kindly provided by A.M.Blom). Incubation was
continued for 1 hour. Following washing 36with TBS, Alkaline
phosphatase conjugated Rabbit anti mouse IgG (1:25 diluted in
TBS containing NRS) was added for 1 hour followed by mouse
APAAP (1:25). After 1 hour sections were washed in TBS pH 8.2,
developed with Fast Red substrate, counterstained with Mayer’s
haematoxylin and mounted prior to assessment. Slides were coded
and assessed blindly by a pathologist (SGH). Distribution of
staining was recorded and the level of intensity of staining
recorded using an established validated method of scoring where –
ve relates to complete absence of staining and +++ represents the
strongest observable level of expression.
In selected cases C4BP and CD40 were co localised using dual
immunofluorescence. For these experiments a polyclonal goat anti
human C4BP (R&D Systems) which gave staining patterns
consistent with the mouse monoclonal reagent was substituted
to avoid cross reactivity with conjugated secondary antibodies.
Briefly snap frozen acetone fixed sections were blocked and then
incubated with the goat anti human C4BP (1:50 dilution) and mouse
anti human CD40. Binding of primary antibodies was detected by
addition of FITC conjugated donkey anti goat IgG and and PE
conjugated rabbitantimouse IgG(Dako). Controlsincluded sections
were primary antibodies were omitted or substituted for non
immune serum or control immunoglobulin. Following staining
sections were mounted inimmunofluorescent mountant (Dako)
allowed to dry and examined using fluorescence microscopy.
Statistical analysis
Statistical analysis was carried out using an unpaired t test. All
primary cell culture experiments were carried out between 3 and
15 times as stated in text and figure legends.
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